In studies involving OV therapy, reducing the recruitment of MDSCs has been a commonly used approach, with compounds and cytokines such as γ-secretase inhibitor (GSI) (Otani et al., 2022), IL-2 (Takehara et al., 2013), IL-36 (Yang et al., 2021), embelin (Wang et al., 2020), trabectedin (Denton et al., 2018), dichloroacetate (Meng et al., 2020), celecoxib (Hou et al., 2016) and indoximod (Nguyen et al., 2022) inhibiting MDSC infiltration through various mechanisms in the tumor microenvironment, thereby boosting the anti-tumor effects when combined with OV therapy. The gene discussed is IL2; the disease is neoplasm.